Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NDAC Calls For Predefined Endpoints In Consumer Behavior Trials

This article was originally published in The Tan Sheet

Executive Summary

Rx-to-OTC switch sponsors will be expected to work with FDA to establish predefined endpoints for each consumer behavior trial they plan, if the agency follows advice given by the Nonprescription Drugs Advisory Committee during a Sept. 25 meeting
Advertisement

Related Content

Draft Label Comprehension Study Guidance Stresses Quality And Quantity
Draft Label Comprehension Study Guidance Stresses Quality And Quantity
From Availability To Awareness: 2007 Brings Wide Range Of Goals For CHPA
DNCE Could Improve NDA Process With More Staffing, Sponsor Meetings
Labels May Need Explicit References To Consequences Of Misuse – Ganley
FDA Clearance May Thwart Monograph Goal; Ganley Talks Turkey About ONP
Sponsors Should Use Comparator Arms In Behavior Studies – NDAC
ONP Has Actual-Use Trial Panel, Rx-To-OTC Switch MaPP In Mind – Ganley
Actual Use, Label Comprehension Guidances Slated For 2006
Actual Use, Label Comprehension Guidances Slated For 2006

Topics

Advertisement
UsernamePublicRestriction

Register

PS099803

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel